In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioVitrum/Amgen: A Sign of Early-Stage Deals to Come

Executive Summary

Biovitrum's record-breaking deal with Amgen--the largest licensing transaction by a European Biotech player to date-secures for Biovitrum the financial and strategic means to help it become a fully integrated biopharmaceutical company. The deal is also strategically important to Amgen, giving the company a way into the primary care segment. But the price and risk are high: there's no clinical proof of efficacy on the compound and there's no competitive compound on the market, or even in late-stage clinical trials, proving the value of the target. Thus the broader implication for the industry: as the costs of late-stage licensing become prohibitive-and the compounds themselves unavailable-in-licensers are increasingly looking to earlier-stage products to bolster their pipelines, with deal prices, and risks, rising correspondingly.
Advertisement

Related Content

Europe's Flavors of Sustainable BioPharma
Amgen Acquires Tularik and Small-Molecule Expertise
Amgen Moves Beyond Proteins
Zealand Deals Diabetes Drug to Aventis
Tularik & Amgen: A Model of Business Development (and Good News for Biotech, Too)
Tularik & Amgen: A Model of Business Development (and Good News for Biotech, Too)
Amylin/Lilly: Resurrections and Conversions
Amylin/Lilly: Resurrections and Conversions
Why Pharma Needs to Do Early-Stage Deals
Why Pharma Needs to Do Early-Stage Deals

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel